LLY•benzinga•
Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal
Summary
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 4, 2025 by benzinga